iBio, Inc. (FWB:0JV0) Financings

iBio, Inc.

Financings

RaiseDate
Private placement of shares of common stock (or pre-funded warrants in lieu thereof)
Announced: about US$26M · US$2.35 a share · Leerink Partners +2
Dealers: Leerink Partners (lead), LifeSci Capital (co-lead), Oppenheimer & Co. (co-lead)
Buyers: Frazier Life Sciences
Use of proceeds: Advance preclinical cardiometabolic programs incl. IBIO-610, IBIO-600 and bispecifics, other pipeline assets, working capital and general corporate purposes
Jan 9, 2026
Public offering of pre-funded warrants and accompanying Series G warrants
Closed: US$50M raised · US$0.699 a share · ½ warrant at US$0.7 · Leerink Partners +3
Dealers: Leerink Partners (lead), LifeSci Capital, Oppenheimer & Co., Brookline Capital Markets
Buyers: Balyasny Asset Management; Cormorant Asset Management; Adage Capital Partners LP; Ally Bridge Group; Marshall Wace; Coastlands Capital; SilverArc Capital Management; Vestal Point Capital; Ausangate Capital
Use of proceeds: Advance preclinical cardiometabolic programs incl. IBIO-610 and IBIO-600, other pipeline assets, working capital and general corporate purposes
Aug 25, 2025
Warrant exercise of shares of common stock upon exercise of existing warrants
Announced: about US$6.2M · US$1.11 a share · Warrants at US$0.86 for 60 months · Chardan
Dealers: Chardan
Use of proceeds: Working capital and other general corporate purposes
Apr 29, 2025
Private placement of private placement offering
Closed: US$650,000 raised
Insiders: Private placement with members of its Board of Directors and Officers
Jan 13, 2025

Read by 6ix AI from the company's releases